Loading
Loading
Hormonal & Fertility Support · 75iu
Janoshik-tested · 6 vials per kit
HMG (Human Menopausal Gonadotropin) is a gonadotropin preparation containing FSH and LH activity studied in preclinical and clinical research for its reproductive properties. Research has examined its potential to stimulate follicular development in females and spermatogenesis support in males. Studies have explored applications in ovarian stimulation protocols and male hypogonadotropic hypogonadism models.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
HMG
Human Menopausal Gonadotropin (Menotropins)
Human Menopausal Gonadotropin (hMG, Menotropins) is a preparation containing both follicle-stimulating hormone (FSH) and luteinising hormone (LH) activity, originally extracted and purified from the urine of post-menopausal women. Modern preparations (Merional, Menopur) typically contain 75 IU FSH and 75 IU LH per ampoule. Highly purified urinary FSH (HP-FSH) and recombinant FSH alternatives are also available.
The FSH component acts via FSHR on Sertoli cells (in males) and granulosa cells (in females) through cAMP/PKA signalling, stimulating spermatogenesis support factors (inhibin B, androgen-binding protein) in males and follicular maturation/oestrogen production in females. The LH component (LHCGR) supports Leydig cell testosterone in males and triggers ovulation/corpus luteum formation in females. In male infertility, combined FSH+LH activity is often required — FSH restores spermatogenesis while LH maintains intratesticular testosterone.
Hypogonadotrophic hypogonadism (male spermatogenesis restoration), female ovarian stimulation protocols, pituitary axis assessment, combined FSH+LH male fertility protocols, and HPG-axis pharmacology. Research continues into optimising FSH:LH ratios for different clinical scenarios and studying gonadotropin receptor genetics affecting treatment response.
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
